SCHEMBL383453

SCHEMBL383453

Cc1ccccc1C[C@@H](N)C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 3/20 0.59
NOS1 P29475 3/20 0.59
NOS2 P35228 3/20 0.59
SLC7A5 Q01650 3/20 0.58
PKM P14618 2/20 0.58
ALPI P09923 1/20 0.58
PTGS1 P23219 1/20 0.58
XIAP P98170 1/20 0.58
MAPT P10636 3/20 0.51
KDM4E B2RXH2 2/20 0.51
MEN1 O00255 2/20 0.51
LMNA P02545 2/20 0.51
BLM P54132 2/20 0.51
PMP22 Q01453 2/20 0.51
KMT2A Q03164 2/20 0.51
HIF1A Q16665 2/20 0.51
MPO P05164 1/20 0.51
TSHR P16473 1/20 0.51
ALDH1A1 P00352 2/20 0.50
RECQL P46063 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL43864 1.00 NOS3 (0.59) NOS3NOS1NOS2SLC7A5PKM
SCHEMBL43865 1.00 NOS3 (0.59) NOS3NOS1NOS2SLC7A5PKM
SCHEMBL29379111 1.00 NOS3 (0.59) NOS3NOS1NOS2SLC7A5PKM
Hydrochloric Acid SCHEMBL28690926 0.98 NOS3 (0.58) NOS3NOS1NOS2SLC7A5PKM
Hydrochloric Acid SCHEMBL28690928 0.98 NOS3 (0.58) NOS3NOS1NOS2SLC7A5PKM
Dl-Phenylalanine SCHEMBL23214377 0.93 SLC7A5 (0.71) NOS3NOS1NOS2SLC7A5PKM
SCHEMBL27464327 0.87 NOS3 (0.48) NOS3NOS1NOS2SLC7A5PKM
SCHEMBL13971424 0.86 SLC7A5 (0.69) NOS3NOS1NOS2SLC7A5PKM
SCHEMBL9164980 0.86 SLC7A5 (0.69) NOS3NOS1NOS2SLC7A5PKM
SCHEMBL5326602 0.86 NOS3 (0.53) NOS3NOS1NOS2SLC7A5PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 349 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120192379-A Marine cyclic peptide and synthesis method and application thereof 内蒙古大学 2025-06-24 CN claimed
EP-3464324-B1 ANGIOTENSIN-1-RECEPTOR ANTAGONISTS FERRING BV (NL) 2021-04-07 EP claimed
US-20200102348-A1 ANGIOTENSIN-1-RECEPTOR ANTAGONISTS FERRING B.V. (NL) 2020-04-02 US claimed
US-10344054-B2 Angiotensin-1-receptor antagonists FERRING B.V. (NL) 2019-07-09 US claimed
EP-3464324-A1 ANGIOTENSIN-1-RECEPTOR ANTAGONISTS Ferring B.V. (NL) 2019-04-10 EP claimed
CN-109311942-A Angiotensin-1 receptor antagonists 辉凌公司 2019-02-05 CN claimed
US-20170349629-A1 Angiotensin-1-Receptor Antagonists FERRING B.V. (NL) 2017-12-07 US claimed
WO-2017207760-A1 ANGIOTENSIN-1-RECEPTOR ANTAGONISTS FERRING B.V. (NL) 2017-12-07 WO claimed
CN-106219911-A The processing system of a kind of rolling effluent and processing method thereof 山东钢铁股份有限公司 2016-12-14 CN claimed
US-20160022636-A1 PHYSIOLOGICAL LIGANDS FOR GPR139 JANSSEN PHARMACEUTICA NV (BE) 2016-01-28 US claimed
CN-101107264-A C5a receptor antagonists JERINI AG (DE) 2008-01-16 CN claimed
JP-2007534619-A 2007-11-29 JP claimed
US-20070254831-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn BIOGEN HEMOPHILIA INC. 2007-11-01 US claimed
EP-1838725-A1 C5A RECEPTOR ANTAGONISTS Jerini AG (DE) 2007-10-03 EP claimed
WO-2007098420-A2 PEPTIDES THAT BLOCK THE BINDING OF IGG TO FCRN SYNTONIX PHARMACEUTICALS, INC. (US) 2007-08-30 WO claimed
US-20060183883-A1 C5a Receptor antagonists JERINI AG (DE) 2006-08-17 US claimed
WO-2006074964-A1 C5A RECEPTOR ANTAGONISTS JERINI AG (DE) 2006-07-20 WO claimed
EP-1646643-A2 C5A RECEPTOR ANTAGONISTS Jerini AG (DE) 2006-04-19 EP claimed
WO-2005010030-A2 C5A RECEPTOR ANTAGONISTS JERINI AG (DE) 2005-02-03 WO claimed
EP-1498422-A1 C5a Receptor Antagonists Jerini AG (DE) 2005-01-19 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170349629-A1 Angiotensin-1-Receptor Antagonists AGTR1, AGTR2, REN NOS3 1053/4885NOS1 956/4885NOS2 1445/4885
US-20200102348-A1 ANGIOTENSIN-1-RECEPTOR ANTAGONISTS AGTR1, AGTR2, REN NOS3 1053/4885NOS1 956/4885NOS2 1445/4885
US-10344054-B2 Angiotensin-1-receptor antagonists AGTR1, AGTR2, AGT NOS3 970/4885NOS1 760/4885NOS2 1182/4885
US-20060183883-A1 C5a Receptor antagonists C5AR1, C3AR1, C5AR2 NOS3 369/4885NOS1 610/4885NOS2 811/4885
US-20070254831-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn FCGRT, FCGR3B, FCGR1A NOS3 1962/4885NOS1 2538/4885NOS2 2254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.